How AI Could End Antidepressants Trial and Error in Clinics
New AI tools promise to end months of antidepressant trial-and-error by mining EEGs, EHRs, and genetic data to predict drug response. Startups race to sell validated workflows, not just demos—raising high-stakes questions about regulation, bias, and who profits. Click to explore the science, money, and clinical fallout and decide fast.
